Montelukast, sold under the brand name Singulair and as generic tablets and granules, is one of the most commonly prescribed maintenance medications for asthma and allergic rhinitis. Patients on daily asthma control medications sometimes ask whether montelukast could trigger an unexpected result on a workplace or clinical urine drug screen. The short answer is that montelukast is not a controlled substance, it is not a target analyte on any standard immunoassay panel, and there is no published cross reactivity evidence linking it to a false positive on a 5, 10, or 12 panel test. This article explains what montelukast is, how workplace drug screening actually works, what the review process looks like if a result is ever disputed, and how montelukast compares to other common asthma and allergy medications.
What montelukast is and how it works
Montelukast is a leukotriene receptor antagonist. It blocks the action of leukotrienes, inflammatory chemicals the body releases that narrow airways and increase mucus in the lungs and nasal passages. Unlike a quick relief inhaler, montelukast is a once daily oral maintenance medication used to prevent asthma symptoms and to manage seasonal and perennial allergic rhinitis. It is not a bronchodilator and it is not taken for immediate relief of an asthma attack. The current prescribing information, including dosing, warnings, and drug interactions, is published on DailyMed, the National Library of Medicine's repository of official drug labels. The Singulair label on DailyMed describes the drug's mechanism, approved uses, and safety information in full.
Is montelukast a controlled substance?
No. Montelukast does not appear on any Drug Enforcement Administration schedule. It has no recognized abuse potential and is not regulated as a controlled substance at the federal level. The DEA publishes and maintains the federal schedules of controlled substances, and the DEA's own scheduling resource confirms which drug classes fall under Schedules I through V. Montelukast, along with other leukotriene receptor antagonists, is not among them. Employers and MROs reviewing a result involving this medication are dealing with an ordinary prescription maintenance drug, not a controlled substance with diversion concerns.
Which panels could montelukast theoretically affect
Standard workplace drug tests, whether a 5 panel, 10 panel, or expanded 12 panel configuration, use immunoassay screening technology designed to detect specific drug classes: amphetamines, cocaine metabolites, opiates, PCP, THC metabolites, and depending on the panel, benzodiazepines, barbiturates, methadone, propoxyphene, and a few others. Each immunoassay strip or cup cassette is built around antibodies that bind to a target drug class and close chemical relatives of that class. Montelukast's chemical structure, a quinoline based leukotriene antagonist, does not resemble any of these target drug classes. It is not part of the amphetamine, opiate, benzodiazepine, cannabinoid, cocaine, or PCP families that immunoassay panels are built to detect. There is no structural reason to expect antibody binding, and no panel marketed for workplace or clinical use lists montelukast as a target analyte or a known interferent.
What the published cross reactivity evidence actually shows
Immunoassay cross reactivity, when a non target substance binds to the antibodies in a screening test and produces a presumptive positive for an unrelated drug class, is a documented phenomenon for a defined list of substances. Decongestants, certain antibiotics, some antidepressants, and a handful of over the counter medications have published case reports or structured interference data describing specific false positive patterns. The authoritative general reference on how these screens work and which drug classes have documented interference issues is the NIH Bookshelf chapter Urine Drug Screening, from StatPearls, which lays out immunoassay methodology and the known categories of cross reactivity. Montelukast and other leukotriene receptor antagonists do not appear among the substances associated with documented immunoassay interference. A search of the published literature returns no credible, peer reviewed reports of montelukast producing a false positive on any standard drug class screen. When no published cross reactivity exists for a medication, the accurate statement is exactly that: no published cross reactivity, not a promise that no result could ever vary across the many immunoassay manufacturers and lot formulations on the market.
How confirmation testing resolves a presumptive result
Immunoassay screening is a presumptive method. It is fast and inexpensive, but it is designed to flag likely positives for further review, not to make a final legal or employment determination on its own. Any non negative screening result that matters for employment, legal, or clinical purposes should go to confirmation testing using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS). These methods separate and identify molecules by their exact mass and structure, which distinguishes the true target drug from any structurally unrelated compound like montelukast. Because montelukast does not share a target molecule's mass signature or metabolic pathway, confirmation testing would not identify it as the substance responsible for a true positive, and it would not explain a positive screen that confirmation testing fails to reproduce. The Substance Abuse and Mental Health Services Administration's workplace program materials describe how certified laboratories apply this two tier screen and confirm model across federally regulated and voluntary testing programs; see SAMHSA's workplace testing resources for program level detail.
The MRO review and prescription documentation
For any DOT regulated or similarly structured program, a certified laboratory reports a non negative result to a Medical Review Officer, a licensed physician trained to interpret drug test results in a clinical and legal context. Under the federal workplace drug testing procedures codified at 49 CFR Part 40, Subpart G, the MRO contacts the tested individual directly, reviews the laboratory result, and asks about any current prescriptions or medical explanations before the result is reported to an employer. If an employee discloses a montelukast prescription, the MRO can request documentation from the pharmacy or prescribing provider, though as explained above, montelukast itself is not expected to produce a positive screen on any standard panel in the first place. The MRO process exists to catch legitimate medical explanations for any positive result, and it is the correct channel for any employee who believes a medication has affected their test, not a dispute handled informally between employee and employer.
What employers should do with a disputed result
If an employee raises a medication as a possible explanation for a non negative result, the employer's role is to route the matter to the MRO or the laboratory's established review process rather than to make an independent judgment about the medication's effects. Employers should never attempt to interpret pharmacology on their own, should not ask for medical details beyond what the MRO process requires, and should treat the MRO's final determination, positive, negative, or canceled, as the operative result for personnel decisions. Employers may want to review their written drug testing policy to confirm it reflects the current MRO review procedure and gives employees a clear path to disclose prescriptions confidentially through the MRO rather than through a supervisor.
Common asthma and allergy medications compared
| Medication | Drug class | Controlled substance | Documented immunoassay interference |
|---|---|---|---|
| Montelukast (Singulair) | Leukotriene receptor antagonist | No | No published cross reactivity |
| Albuterol | Short acting beta2 agonist bronchodilator | No | Reports exist for some amphetamine immunoassay formulations; confirmation testing resolves it |
| Inhaled corticosteroids (fluticasone, budesonide) | Corticosteroid | No | No published cross reactivity |
| Cetirizine (Zyrtec) | Second generation antihistamine | No | No published cross reactivity for cetirizine itself; combination products with pseudoephedrine carry separate amphetamine class considerations |
| Diphenhydramine (Benadryl) | First generation antihistamine | No | Isolated case reports involving some PCP immunoassay formulations; confirmation testing resolves it |
This table reflects publicly documented interference patterns and is not exhaustive. Immunoassay kits vary by manufacturer and lot, and a result that matters should always move to confirmation testing and MRO review rather than being decided from a table.
Where this fits for employers building a testing program
American Screening Corporation supplies drug test cups and dip cards used in employer and clinical testing programs. Programs that screen for the standard drug classes described above rely on devices that are manufactured to consistent, documented specifications, and any employer building out a program should pair device selection with a clear MRO review pathway and a written policy on prescription disclosure. Employers sourcing testing supplies in volume can review device options through the drug test cup collection on americanscreeningcorp.com, and buyers purchasing for a business account can also review the wholesale portal at wholesale.americanscreeningcorp.com.
For background on how the MRO review step works in more detail, see our related post on the Medical Review Officer process. For a look at a different asthma medication and its relationship to amphetamine class screening, see our post on whether albuterol causes a false positive drug test.
Frequently asked questions
Does montelukast show up as a positive on a standard drug test?
No. Montelukast is not a target analyte on any standard 5, 10, or 12 panel immunoassay, and there is no published cross reactivity evidence linking it to a false positive on any standard drug class screen.
Is montelukast a controlled substance?
No. Montelukast does not appear on any DEA controlled substance schedule and has no recognized abuse potential.
What should an employee do if they take montelukast and are being tested?
Employees are not required to disclose an asthma or allergy prescription before testing. If a question arises, the Medical Review Officer process is the correct channel to review any current prescriptions as part of a non negative result review.
Can a confirmation test tell the difference between montelukast and a target drug?
Yes. GC/MS and LC/MS/MS confirmation testing identify substances by exact molecular structure and mass, which distinguishes montelukast from any structurally unrelated target drug class.
Do other asthma medications carry more cross reactivity risk than montelukast?
Some stimulant type bronchodilators like albuterol have isolated reports of interference with certain amphetamine immunoassay formulations, while inhaled corticosteroids and montelukast do not have documented interference reports.
Who reviews a positive drug test result involving a prescription medication?
A Medical Review Officer, a licensed physician trained in this review process, contacts the individual and reviews any medical explanation or prescription documentation before a final result is reported to the employer, under the procedures in 49 CFR Part 40.
This article is general information about drug testing science and procedure, not medical or legal advice. Employees with questions about a specific medication or test result should speak with the Medical Review Officer assigned to their test or their own physician.